TY - JOUR

T1 - Impact of age and comorbidities on SARS-CoV-2 vaccine-induced T cell immunity

AU - Dietz, Lisa Lokso

AU - Juhl, Anna Karina

AU - Sogaard, Ole Schmeltz

AU - Reekie, Joanne

AU - Nielsen, Henrik

AU - Johansen, Isik Somuncu

AU - Benfield, Thomas

AU - Wiese, Lothar

AU - Staerke, Nina Breinholt

AU - Jensen, Tomas Ostergaard

AU - Jakobsen, Stine Finne

AU - Olesen, Rikke

AU - Iversen, Kasper

AU - Fogh, Kamille

AU - Bodilsen, Jacob

AU - Petersen, Kristine Toft

AU - Larsen, Lykke

AU - Madsen, Lone Wulff

AU - Lindvig, Susan Olaf

AU - Holden, Inge Kristine

AU - Raben, Dorthe

AU - Andersen, Sidsel Dahl

AU - Hvidt, Astrid Korning

AU - Andreasen, Signe Rode

AU - Baerends, Eva Anna Marianne

AU - Lundgren, Jens

AU - Østergaard, Lars

AU - Tolstrup, Martin

AU - ENFORCE Study Grp

PY - 2023

Y1 - 2023

N2 - Dietz, Juhl et al. examine the cellular and humoral immune response to SARS-CoV-2 in 655 Danish older citizens that received their SARS-CoV-2 vaccine. The findings provide insight into the impact of age and disease burden on SARS-CoV2 vaccine-induced T cell immunity.Plain language summaryVaccination has proven very effective in protecting against severe disease and hospitalization of people with COVID-19, the disease caused by SARS-CoV-2. It is still unclear, however, how the different components of the immune system respond to SARS-CoV-2 vaccination and protect from infection and severe disease. Two of the most predominant components of the immune system are specialized proteins and cells. The proteins circulate in the blood and help clear the virus by binding to it, while the cells either kill the virus or help other cells to produce more antibodies. Here, we examined the response of these two components to the SARS-CoV-2 vaccine in 655 Danish citizens. The response of both components was lower in people over 75 years old and with other diseases. These findings help in understanding the immune responses following SARS-CoV-2 vaccination in people at increased risk of severe symptoms of COVID-19.BackgroundOlder age and chronic disease are important risk factors for developing severe COVID-19. At population level, vaccine-induced immunity substantially reduces the risk of severe COVID-19 disease and hospitalization. However, the relative impact of humoral and cellular immunity on protection from breakthrough infection and severe disease is not fully understood.MethodsIn a study cohort of 655 primarily older study participants (median of 63 years (IQR: 51-72)), we determined serum levels of Spike IgG antibodies using a Multiantigen Serological Assay and quantified the frequency of SARS-CoV-2 Spike-specific CD4 + and CD8 + T cells using activation induced marker assay. This enabled characterization of suboptimal vaccine-induced cellular immunity. The risk factors of being a cellular hypo responder were assessed using logistic regression. Further follow-up of study participants allowed for an evaluation of the impact of T cell immunity on breakthrough infections.ResultsWe show reduced serological immunity and frequency of CD4 + Spike-specific T cells in the oldest age group (>= 75 years) and higher Charlson Comorbidity Index (CCI) categories. Male sex, age group >= 75 years, and CCI > 0 is associated with an increased likelihood of being a cellular hypo-responder while vaccine type is a significant risk factor. Assessing breakthrough infections, no protective effect of T cell immunity is identified.ConclusionsSARS-CoV-2 Spike-specific immune responses in both the cellular and serological compartment of the adaptive immune system increase with each vaccine dose and are progressively lower with older age and higher prevalence of comorbidities. The findings contribute to the understanding of the vaccine response in individuals with increased risk of severe COVID-19 disease and hospitalization.

AB - Dietz, Juhl et al. examine the cellular and humoral immune response to SARS-CoV-2 in 655 Danish older citizens that received their SARS-CoV-2 vaccine. The findings provide insight into the impact of age and disease burden on SARS-CoV2 vaccine-induced T cell immunity.Plain language summaryVaccination has proven very effective in protecting against severe disease and hospitalization of people with COVID-19, the disease caused by SARS-CoV-2. It is still unclear, however, how the different components of the immune system respond to SARS-CoV-2 vaccination and protect from infection and severe disease. Two of the most predominant components of the immune system are specialized proteins and cells. The proteins circulate in the blood and help clear the virus by binding to it, while the cells either kill the virus or help other cells to produce more antibodies. Here, we examined the response of these two components to the SARS-CoV-2 vaccine in 655 Danish citizens. The response of both components was lower in people over 75 years old and with other diseases. These findings help in understanding the immune responses following SARS-CoV-2 vaccination in people at increased risk of severe symptoms of COVID-19.BackgroundOlder age and chronic disease are important risk factors for developing severe COVID-19. At population level, vaccine-induced immunity substantially reduces the risk of severe COVID-19 disease and hospitalization. However, the relative impact of humoral and cellular immunity on protection from breakthrough infection and severe disease is not fully understood.MethodsIn a study cohort of 655 primarily older study participants (median of 63 years (IQR: 51-72)), we determined serum levels of Spike IgG antibodies using a Multiantigen Serological Assay and quantified the frequency of SARS-CoV-2 Spike-specific CD4 + and CD8 + T cells using activation induced marker assay. This enabled characterization of suboptimal vaccine-induced cellular immunity. The risk factors of being a cellular hypo responder were assessed using logistic regression. Further follow-up of study participants allowed for an evaluation of the impact of T cell immunity on breakthrough infections.ResultsWe show reduced serological immunity and frequency of CD4 + Spike-specific T cells in the oldest age group (>= 75 years) and higher Charlson Comorbidity Index (CCI) categories. Male sex, age group >= 75 years, and CCI > 0 is associated with an increased likelihood of being a cellular hypo-responder while vaccine type is a significant risk factor. Assessing breakthrough infections, no protective effect of T cell immunity is identified.ConclusionsSARS-CoV-2 Spike-specific immune responses in both the cellular and serological compartment of the adaptive immune system increase with each vaccine dose and are progressively lower with older age and higher prevalence of comorbidities. The findings contribute to the understanding of the vaccine response in individuals with increased risk of severe COVID-19 disease and hospitalization.

KW - STATISTICS

KW - RESPONSES

U2 - 10.1038/s43856-023-00277-x

DO - 10.1038/s43856-023-00277-x

M3 - Journal article

C2 - 37095240

VL - 3

JO - Communications Medicine

JF - Communications Medicine

SN - 2730-664X

IS - 1

M1 - 58

ER -